Northstar Oncology by BillionToOne released its newest test, Northstar Origin, which runs on the same Northstar Select sample and delivers results in 5–8 days.
Published
Signal category
Products & Services
Quote
“Our newest test, Northstar Origin™, helps answer questions around tissue of origin and cancer of unknown primary.”
— Northstar Oncology by BillionToOne team
Company
- Industry
- Biotechnology Research
- Location
- Menlo Park, US
- Company size
- 22 employees
Northstar Oncology delivers precision liquid biopsy tests to improve cancer care. Our platform is built to detect actionable signals others may miss, empowering providers to navigate therapy selection and monitor response with clarity and confidence. → Northstar Select® is the most sensitive ctDNA-based therapy selection profile, uncovering over 50% more clinically actionable information and reducing false negative null reports by half. → Northstar Response® is the only tissue-free methylation-based treatment monitoring test with single-molecule precision that offers real-time insights into molecular progression. Northstar delivers the clarity providers need to plan treatment confidently—giving patients a clearer path forward. See how Northstar can help optimize treatment planning for advanced cancers → www.northstaronc.com